The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Deleterious alterations of DNA damage response and repair (DDR) genes in association with clinical benefit to programmed cell death protein-1 (PD-1)/PD ligand 1 (PD-L1)-based therapy in esophageal squamous cell carcinoma (ESCC).
 
Jhe-Cyuan Guo
Honoraria - Astellas Pharma; MSD; Ono Pharmaceutical
 
Chia-Chi Lin
Honoraria - Daiichi Sankyo; Novartis; Roche
Consulting or Advisory Role - Blueprint Medicines; Boehringer Ingelheim; Novartis
Travel, Accommodations, Expenses - BeiGene; Daiichi Sankyo; Lilly; Novartis
 
Ta-Chen Huang
No Relationships to Disclose
 
Chun-Jung Chang
No Relationships to Disclose
 
Hung-Yang Kuo
Speakers' Bureau - Sanofi
 
Chih-Hung Hsu
Honoraria - Bristol-Myers Squibb; Merck Sharp & Dohme; Ono Pharmaceutical
Consulting or Advisory Role - Bristol-Myers Squibb; Lilly; Merck Serono; MSD; Novartis; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Merck Sharp & Dohme